ArticleBMC psychiatry2025
Associations of leptin levels with psychopathology, BDNF and inflammatory cytokines in patients with chronic schizophrenia as well as gender differences.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurotrophins and Galectin-3: Hidden Keys in Neuroinflammation-A Narrative Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndrome significantly contributes to mortality among individuals suffering from chronic schizophrenia (CS), and there is a strong correlation between this condition and plasma leptin (LEP) levels. However, there are relatively few studies on the factors affecting leptin levels in chronic schizophrenia, and findings are often inconsistent. The purpose of this study was to investigate the leptin levels and their association with psychopathology, BDNF and inflammatory cytokines in patients with chronic schizophrenia, as well as potential gender differences.
methodsThe study enrolled 301 individuals diagnosed with chronic schizophrenia. Participants were assessed for psychotic symptoms, insomnia severity, and depressive symptoms using the Positive and Negative Syndrome Scale (PANSS), Insomnia Severity Index (ISI), and Calgary Depression Scale for Schizophrenia (CDSS), respectively. Leptin, BDNF and inflammatory cytokines levels were also detected.
resultsAmong the patients, Log LEP levels were positively correlated with females, body mass index (BMI), systolic and diastolic blood pressures, Log BDNF, Log IL-6, and Log IL-17 A levels, and negatively correlated with the total score on the PANSS, as well as scores on the positive, negative, and general psychopathology subscales (all p < 0.05). Multiple linear regression analyses revealed that Log LEP levels were independently correlated with gender (β = 0.514, t = 15.601, p < 0.001), BMI (β = 0.053, t = 12.096, p < 0.001), diastolic blood pressure (β = 0.005, t = 2.334, p = 0.020), and Log IL-17 A levels (β = 0.062, t = 2.097, p = 0.037). Notably, these associations between leptin and the above factors were only observed in the male patients.
conclusionsA significant link was identified between leptin levels and the presence of psychotic symptoms, BDNF, and inflammatory cytokines (especially IL-6 and IL-17 A) in individuals suffering from chronic schizophrenia, with notable variations observed between genders. Future research, including more longitudinal studies and animal models, is necessary to delve deeper into these associations and uncover their underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.